Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCG priming and Pfizer-BioNTech COVID-19 vaccine immunogenicity in health care workers
NL-OMON50881Phase 4Active, not recruiting
- Sponsor
- Interne Geneeskunde
- Start
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of bcg vaccine and tozinameran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Interne Geneeskunde. Primary endpoints: Serological IgG titer to SARS-CoV-2 spike protein at 6 months and Serological IgG titer to SARS-CoV-2 spike protein at 12 months. Started Apr 2021; status: active, not recruiting.
02
Drugs
bcg vaccinetozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON50881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50881.